title: [Nedaplatin combined with tegafur in the treatment for advanced esophageal cancer].
abstract: OBJECTIVE
  To investigate the efficacy and toxicity of nedaplatin combined with tegafur in the treatment for patients with advanced esophageal cancer.
  
  
  METHODS
  Among the 65 patients with advanced esophageal cancer, 27 had no history of prior chemotherapy and the other 38 had ever received postoperative adjuvant chemotherapy before. The median age of those cases was 58.0 years. Nedaplatin was given daily by intravenous infusion at a dose of 20 mg/m(2) for 2 hours and tegafur at a dose of 500 mg/m(2) for 8 hours on D1 approximately D5, every 21 days as a cycle.
  
  
  RESULTS
  193 cycles of chemotherapy were accomplished in the 65 patients, and 63 patients were evaluable for response evaluation. Of 27 patients with no prior history of chemotherapy, 6 achieved complete response and 16 partial response, with a response rate (CR + PR) of 81.5%. Among the 36 patients who had ever received postoperative adjuvant chemotherapy, 6 obtained complete response and 10 partial response with a response rate (CR + PR) of 44.4%. The overall median time to tumor progression in this series was 5.6 months. The overall median actuarial survival was 9.3 months, and the one-year survival rate was 24.9%. Nausea and vomiting were the major toxicities, but were mild and well tolerable. Grade 3 to 4 neutropenia was only observed in two patients (3.2%).
  
  
  CONCLUSIONS
  The regimen of nedaplatin combined with tegafur is effective and tolerable for the treatment of advanced esophageal cancer.
authors.affiliation: Depratment of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China.
authors.forename: Qing-Xia
authors.initials: QX
authors.lastname: Fan
authors.forename: Rui
authors.initials: R
authors.lastname: Wang
authors.forename: Ping
authors.initials: P
authors.lastname: Lu
authors.forename: Yong-Fu
authors.initials: YF
authors.lastname: Zhao
authors.forename: Tai-Ying
authors.initials: TY
authors.lastname: Lu
authors.forename: Jian-Wei
authors.initials: JW
authors.lastname: Han
authors.forename: Jun-Sheng
authors.initials: JS
authors.lastname: Wang
authors.forename: Su-Xia
authors.initials: SX
authors.lastname: Luo
authors.forename: Shou-Ping
authors.initials: SP
authors.lastname: Lu
authors.forename: Gui-Ji
authors.initials: GJ
authors.lastname: Wang
authors.forename: Li
authors.initials: L
authors.lastname: Geng
authors.forename: Ming-Zhi
authors.initials: MZ
authors.lastname: Zhang
authors.forename: Zhi-Yong
authors.initials: ZY
authors.lastname: Ma
authors.forename: Min
authors.initials: M
authors.lastname: Song
authors.forename: Xin-Ai
authors.initials: XA
authors.lastname: Wu
authors.forename: Xiao-Bing
authors.initials: XB
authors.lastname: Chen
authors.forename: Zhi-Min
authors.initials: ZM
authors.lastname: Jiao
authors.forename: Rui-Lin
authors.initials: RL
authors.lastname: Wang
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy / Q000473:pathology; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000473:pathology; D004938:Esophageal Neoplasms / Q000188:drug therapy* / Q000473:pathology; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced; D009367:Neoplasm Staging; D009503:Neutropenia / Q000139:chemically induced; D009944:Organoplatinum Compounds / Q000008:administration & dosage / Q000009:adverse effects; D012074:Remission Induction; D015996:Survival Rate; D005641:Tegafur / Q000008:administration & dosage / Q000009:adverse effects; D014839:Vomiting / Q000139:chemically induced
chemical_list: D009944:Organoplatinum Compounds; D005641:Tegafur; C053989:nedaplatin